Advances in therapeutic drug monitoring for triazole antifungal agents

Abstract

Abstract: In recent years, the fungal infection, especially the invasive deep fungal infection has becomes a major threat to patients' health and life. Hence, the research and application of antifungal drugs have been paid much more attention than before. The triazole antifungals, such as fluconazole, itraconazole, voriconazole, are some of the most widely used antifungal agents in clinical. Due to the different absorption, metabolism, elimination and interaction with combined medications, the triazole antifungals exhibit remarkable individual difference in blood concentration. Related clinical trials have proved the reasonable relationship between the drug concentration and the clinical effect, at the same time the relationship between drug concentration and toxicity has also been identified. The use of therapeutic drug monitoring (TDM) for these triazoles can optimize their therapeutic effects while reduce possible side effects. This paper summarizes the domestic and international researches on therapeutic drug monitoring of triazole antifungal drugs.

Key words: therapeutic drug monitoring, voriconazole, posaconazole, fungal infections

CLC Number:

R969.1

ZHAN Ying, SHU Nan, GUO Nan, SHAO Hua, LI Wei-lan. Advances in therapeutic drug monitoring for triazole antifungal agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 706-711.

References

[1] Trifilio S. Update on antifungal drug dosing and therapeutic drug monitoring[J]. Curr Fungal Infect Rep, 2011, 5(3): 92-102.
[2] Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications[J]. Antimicrob Agents Chemother, 2009, 53(1): 24-34.
[3] Traunmüller F, Popovic M, Konz KH, et al. Efficacy and safety of current drug therapies for invasive aspergillosis[J]. Pharmacol, 2011, 88(4): 213-224.
[4] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(1): 327-360.
[5] Hagihara M, Kasai H, Umemura T, et al. Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units[J]. J Infect Chemother, 2011, 17(4): 224-230.
[6] Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 patients[J]. J Clin Oncol, 2003, 21(9): 4615-4626.
[7] Howard SJ, Hope WW. Antifungal therapeutic drug monitoring for invasive aspergillosis[EB/OL]. Aspergillosis: From Diagnosis to Prevention: Springer; 2010, 217-228.
[8] 沈斌. 三唑类抗真菌药代谢性相互作用研究[A]. 2012年浙江省医学会临床药学学术年会暨医院药事管理质控中心、临床药学分会十周年庆典大会论文集[C]. 2012: 327-331.
[9] Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update[J]. J Antimicro chemother, 2008, 61(5): 17-25.
[10]Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities[J]. J Clin Pharmacol, 2006, 46(5): 235-243.
[11]Gómez-López A, Cendejas-Bueno E, Cuesta I, et al. Voriconazole serum levels measured by high- performance liquid chromatography: a monocentric study in treated patients[J]. Med Mycol, 2012, 50(3): 439-445.
[12]Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children[J]. Clin Infect Dis, 2010, 50(4): 27-36.
[13]Dolton MJ, Ray JE, Chen SC-A, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring[J]. Antimicro Agents Chemother, 2012, 56(2): 4793-4799.
[14]Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients[J]. Antimicro Agents Chemother, 2011, 55(1): 4782-4788.
[15]Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole[J]. J Clin Pharmacol, 2009, 49(5): 196-204.
[16]Hussaini T, Rüping MJGT, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole[J]. J Hum Pharmacol Drug Thera, 2011, 31(4): 214-225.
[17]Pasqualotto AC, Xavier MO, Andreolla HF, et al. Voriconazole therapeutic drug monitoring: focus on safety[J]. Exp Opin Drug safe, 2010, 9(11): 125-137.
[18]Brüggemann RJM, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole[J]. Therap Drug Monit, 2008, 30(3): 403-411.
[19]Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice[J]. J Chemother, 2012, 24(12): 311-327.
[20]Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial[J]. Clin Infect Dis, 2012, 55: 1080-1087.
[21]Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity[J]. Antimicro Agents Chemother, 2012, 56(3): 2371-2377.
[22]Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience[J]. Mycoses, 2012, 55(6): 483-492.
[23]Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole[J]. Clin Pharmacokine, 2006, 45(22): 649-63.
[24]Thompson GR, Cadena J, Patterson TF. Overview of antifungal agents[J]. Clin Chest Med, 2009, 30(14): 203-215.
[25]Aperis G, Alivanis P. Posaconazole: A new antifungal weapon[J]. Rev Recent Clin Trials, 2011, 6(3): 204-219.
[26]Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults[J]. Antimicro Agents Chemother, 2009, 53(3): 5224-5229.
[27]Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy[J]. Antimicro Agents Chemother, 2011, 55(24): 1308-1311.
[28]Eiden C, Meniane J, Peyrière H, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake[J]. Euro J Clin Microbiol Infect Dis, 2012, 31(2): 161-167.
[29]Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis[J]. Clin Infect Dis, 2010, 51(1): 1383-1391.